Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer

Clinical Therapeutics

Volumn 27, Issue 3, 2005, Pages 327-335

  Jansman, Frank G A ^a,b   Idzinga, Froukje S F ^a,b   Smit, Willem M ^c   De Graaf, Jacques C ^a   Coenen, Jules L L M ^a   Sleijfer, Dirk Th ^d   Brouwers, Jacobus R B J ^b  

^a Isala Klinieken ^*  (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adverse effects; Chemotherapy; Colorectal neoplasms; Drug interactions; Epidemiology; Irinotecan; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; APREPITANT; ATAZANAVIR; BACITRACIN; BENZODIAZEPINE; CAPECITABINE; CITALOPRAM; CYCLOSPORIN; DEXAMETHASONE; DRUG METABOLITE; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; HANGE SHASHIN TO; HOMEOPATHIC AGENT; HYPERICUM PERFORATUM EXTRACT; IMMUNOMODULATING AGENT; IRINOTECAN; KETOCONAZOLE; LIVE VACCINE; LOPERAMIDE; METOCLOPRAMIDE; NEOMYCIN; NEUROMUSCULAR BLOCKING AGENT; OXALIPLATIN; PHENOBARBITAL; PHENYTOIN; ROTAVIRUS VACCINE; SUXAMETHONIUM; THALIDOMIDE; TROPISETRON; VALPROIC ACID;

ARTICLE; CLASSIFICATION; COLORECTAL CANCER; DIARRHEA; EMBASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERGLYCEMIA; INFECTION COMPLICATION; LYMPHOCYTOPENIA; MEDICAL LITERATURE; MEDLINE; METASTASIS; NONHUMAN; PRESCRIPTION; PUBLICATION; RHABDOMYOLYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS;

EID: 18844370951     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.03.001     Document Type: Article

References (46)

1. [in Dutch] Jansman F.G.A., Jansen J.A., and Coenen J.L.L.M. Clinically relevant fluorouracil + leucovorin interactions in patients with colorectal cancer Pharm Weekbl. 139 2004 1392 1396
2. Grothey A., Sargent D., Goldberg R.M., and Schmoll H.J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment J Clin Oncol. 22 2004 1209 1214
3. Braun A.H., Achterrath W., and Wilke H. New systemic frontline treatment for metastatic colorectal carcinoma Cancer 100 2004 1558 1577
4. Campto [product information] 2003 Aventis Pharma BV Hoevelaken, the Netherlands
5. Eloxatin [product information] 2004 Sanofi-Synthélabo BV Maassluis, the Netherlands
6. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics. Available at: http://www.whocc.no. Accessed September 1, 2004.
7. Tatro D.S. Drug Interaction Facts 2004 Facts and Comparisons St Louis, Mo
8. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
9. Irinotecan[Drugdex drug evaluations]. Healthcare Series Vol 121, expires 9/2004.
10. Oxaliplatin [Drugdex drug evaluations]. Healthcare SeriesVol 121, expires 9/2004.
11. Sjoqvist F. FASS 2000 2000 LINFO Drug Information Ltd Stockholm, Sweden 1481 1486
12. Stockley I.H. Stockley's Drug Interactions 6th ed. 2002 Pharmaceutical Press London
13. Hansten P.D., and Horn J.R. Drug Interactions 2001 Facts and Comparisons St Louis, Mo
14. Note for guidance on the investigation of drug interactions 1997 EMEA/CPMP London
15. Illiger H.J., Bornmann L., and Herdrich K. Drug Interactions in the Therapy of Malignant Diseases 2001 ASTA Medica Oncology Frankfurt, Germany
16. McLeod H.L. Clinically relevant drug-drug interactions in oncology Br J Clin Pharmacol. 45 1998 539 544
17. Moosa A., Dobish R., and Watts C. Interacting with drugs used in oncology:An Alberta Cancer Board initiative J Oncol Pharm Practice 9 2003 87 107
18. Loadman P.M., and Bibby M.C. Pharmacokinetic drug interactions with anticancer drugs Clin Pharmacokinet. 26 1994 486 500
19. Van Meerten E., Verweij J., and Schellens J.H. Antineoplastic agents. Drug interactions of clinical significance Drug Saf. 12 1995 168 182
20. Lam M.S.H., and Ignoffo R.J. A guide to clinically relevant drug interactions in oncology J Oncol Pharm Practice 9 2003 45 85
21. Beijnen J.H., and Schellens J.H. Drug interactions in oncology Lancet Oncol. 5 2004 489 496
22. Sparreboom A., Cox M.C., Acharya M.R., and Figg W.D. Herbal remedies in the United States: Potential ad verse interactions with anticancer agents J Clin Oncol. 22 2004 2489 2503
23. Emend [product information] 2003 Merck Sharp & Dohme Ltd Hertfordshire, UK
24. 2004 Bristol-Myers Squibb Pharma EEIG Hounslow, UK
25. Herben V.M., Ten Bokkel Huinink W.W., Schellens J.H., and Beijen J.H. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors Pharm World Sci. 20 1998 161 172
26. Gupta E., Safa A.R., Wang X., and Ratain M.J. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A Cancer Res. 56 1996 1309 1314
27. Richards S., Umbreit J.N., and Fanucchi M.P. Selective serotonin reuptake inhibitor-induced rhabdomyolysis associated with irinotecan South Med J. 96 2003 1031 1033
28. Friedman H.S., Petros W.P., and Friedman A.H. Irinotecan therapy in adults with recurrent or progressive malignant glioma J Clin Oncol. 17 1999 1516 1525
29. Kehrer D.F.S., Mathijssen R.H., and Verweij J. Modulation of irinotecan metabolism by ketoconazole J Clin Oncol. 20 2002 3122 3129
30. Haaz M.C., RivorY L., and Riche C. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P-450 3A and drug interactions Cancer Res. 58 1998 468 472
31. Santos A., Zanetta S., and Crested T. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans Clin Cancer Res. 6 2000 2012 2020
32. [published correction appears in MMWR Morb Mortal Wkly Rep. 1989;38:311] General recommendations on immunization MMWR Morb Mortal Wkly Rep. 38 1989 205 214
33. [published correction appears in MMWR Morb Mortal Wkly Rep. 1989;38:311] General recommendations on immunization MMWR Morb Mortal Wkly Rep. 38 1989 219 227
34. Rivory L.P., Bowles M.R., Robert J., and Pond S.M. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase Biochem Pharmacol. 52 1996 1103 1111
35. Alimonti A., Satta F., and Pavese I. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhea by oral administration of neomycin plus bacitracin in first-line treatmentof advanced colorectal cancer Ann Oncol. 14 2003 805 806
36. Alimonti A., Gelibter A., and Pavese I. New approaches to prevent intestinal toxicity of irinotecan-based regimens Cancer Treat Rev. 30 2004 555 562
37. Kehrer D.F., Sparreboom A., and Verweij J. Modulation of irinotecaninduced diarrhea by cotreatment with neomycin in cancer patients Clin Cancer Res. 7 2001 1136 1141
38. Gupta E., Wang X., Ramirez J., and Ratain M.J. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and Phenobarbital Cancer Chemother Pharmacol. 39 1997 440 444
39. Mathijssen R.H., Sparreboom A., and Dumez H. Altered irinotecan metabolism in a patient receiving phenytoin Anticancer Drugs. 13 2002 139 140
40. Mathijssen R.H.J., Verweij J., and de Bruijn P. Effects of St. John's wort on irinotecan metabolism J Natl Cancer Inst. 94 2002 1247 1249
41. Govindarajan R., Heaton K.M., and Broadwater R. Effect of thalidomide on gastrointestinal toxic effects of irinotecan Lancet 356 2000 566 567
42. [in Japanese] Sakata Y., Suzuki H., and Kamataki T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diar rhea induced by irinotecan hydrochloride (CPT-11) Can To Kagaku Ryoho 21 1994 1241 1244
43. Bray F., Sankila R., Ferlay J., and Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995 Eur J Cancer 38 2002 99 166
44. Jansman F.G., Sleijfer D.T., and de Graaf J.C. Management of chemotherapyinduced adverse effects in the treat ment of colorectal cancer Drug Saf. 24 2001 353 367
45. Culy C.R., Clemett D., and Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical effi cacy in metastatic colorectal cancer and its potential in othermalignancies Drugs 60 2000 895 924
46. Roberts J.S., Watrous M.L., and Schulz R.M. Quantifying the clinical significance of drug-drug interac tions: Scaling pharmacists' perception of a common interaction classification scheme Ann Pharmacother 30 1996 926 934